Outcomes after primary tumor resection of metastatic pancreatic neuroendocrine tumors: An analysis of the National Cancer Database

Editorial Material Oncology

A Framework for Reporting Cohort Derivation in Studies Using the National Cancer Database

Sarah R. Kaslow et al.

ANNALS OF SURGICAL ONCOLOGY (2022)

Article Oncology

Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis

Sarah R. Kaslow et al.

Summary: This study assessed treatment patterns and outcomes for poorly differentiated pancreatic neuroendocrine carcinoma and found that surgical resection was strongly associated with improved overall survival.

ANNALS OF SURGICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

The Landmark Series: Pancreatic Neuroendocrine Tumors

Jordan M. Cloyd et al.

Summary: PNETs are a rare type of tumor originating from pancreatic islet cells, with surgical resection being the standard treatment for most patients and pancreas-preserving approaches being acceptable for smaller tumors. Observation is recommended for small, low-grade PNETs.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Surgery

Role of Primary Tumor Resection for Metastatic Small Bowel Neuroendocrine Tumors

Julie Hallet et al.

Summary: The debate over resection of the primary tumor in stage IV small bowel neuroendocrine tumors (SB-NETs) continues, with reported survival benefits conflicting due to selection bias. The main clinical benefits of primary tumor resection include prevention of debilitating complications. Assessment and surgical management by experienced surgeons is recommended to consider resection of the primary tumor despite metastatic disease.

WORLD JOURNAL OF SURGERY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis

Diamantis Tsilimigras et al.

Summary: Primary tumor resection (PTR) is associated with improved overall survival (OS) in patients with stage IV gastrointestinal neuroendocrine tumors (GI-NET), especially for those with small intestinal NET and colon NET. However, PTR of rectal NET does not provide a survival benefit.

JOURNAL OF GASTROINTESTINAL SURGERY (2021)

Add to Collection

Article Oncology

Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial

Yukihide Kanemitsu et al.

Summary: This study investigated whether primary tumor resection (PTR) before chemotherapy improves survival in patients with colorectal cancer (CRC) with asymptomatic primary tumor and synchronous unresectable metastases. The results showed that PTR followed by chemotherapy did not provide a survival benefit over chemotherapy alone for CRC patients with asymptomatic primary tumors and synchronous unresectable metastases.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Surgery

Survival Benefit of Primary Tumor Resection Among Elderly Patients with Pancreatic Neuroendocrine Tumors

Junya Toyoda et al.

Summary: Approximately 2 in 5 elderly patients with pNETs underwent PSS. While PSS was generally associated with prolonged OS and CSS among older patients, PSS was not associated with improved CSS among a subset of patients aged 80 or older, as well as among patients age >= 70 years with NF-pNET less than 2 cm.

WORLD JOURNAL OF SURGERY (2021)

Add to Collection

Article Gastroenterology & Hepatology